Dublin, Nov. 22, 2024 (GLOBE NEWSWIRE) -- The "Biotherapeutics Cell Line Development - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The global market for Biotherapeutics Cell Line Development was estimated at US$99.0 Million in 2023 and is projected to reach US$150.7 Million by 2030, growing at a CAGR of 6.2% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. 
The growth in the biotherapeutics cell line development market is driven by several factors, including the rising demand for biologic drugs, advancements in gene editing technologies, and the increasing focus on personalized medicine. The need for efficient, scalable production processes for monoclonal antibodies, biosimilars, and gene therapies is a key driver of market growth.
Additionally, the adoption of automation and AI in cell line selection and optimization is enhancing productivity and reducing development timelines. The regulatory push for faster approval processes for biologics and biosimilars, combined with increased investment in biopharmaceutical R&D, is further fueling the demand for advanced cell line development solutions.
Why Is Cell Line Development Crucial for Biotherapeutics?
Cell line development is a critical step in the production of biotherapeutics, as it involves creating stable cell lines that can efficiently produce therapeutic proteins, antibodies, and other biologic drugs. This process is essential for ensuring the high yield, consistency, and safety of biotherapeutics used to treat various diseases, including cancer, autoimmune disorders, and genetic conditions.
The development of robust cell lines is a complex and time-intensive process, requiring precise genetic modifications and rigorous screening to identify cells with the desired characteristics. As the demand for biologics continues to grow, the need for efficient cell line development techniques has become increasingly important in the biopharmaceutical industry.
What Innovations Are Enhancing Cell Line Development Processes?
Technological innovations are revolutionizing the cell line development process, making it faster, more efficient, and more precise. Advances in gene editing tools like CRISPR-Cas9 are allowing for more accurate genetic modifications, leading to the creation of cell lines with enhanced productivity and stability. Automation and high-throughput screening technologies are also streamlining the selection and optimization of cell lines, significantly reducing the time required for development. Additionally, the use of artificial intelligence (AI) and machine learning in predictive modeling is helping researchers identify optimal cell lines more quickly, improving the overall efficiency of biotherapeutic production.
Which Therapeutic Areas Are Driving the Demand for Biotherapeutic Cell Lines?
The demand for biotherapeutic cell line development is being driven by the rising prevalence of chronic diseases and the growing need for biologics in therapeutic areas such as oncology, immunology, and infectious diseases. Monoclonal antibodies, which are widely used in cancer treatment, rely heavily on efficient cell line development for large-scale production.
Similarly, the development of cell lines for producing biosimilars - lower-cost alternatives to branded biologics - is also gaining momentum as the market for affordable biologics expands. Additionally, the increasing focus on gene and cell therapies is creating new opportunities for specialized cell line development, particularly in personalized medicine and regenerative medicine.
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players in the Global Biotherapeutics Cell Line Development Market such as AGC Biologics, Beckman Coulter, Inc., Becton, Dickinson & Company, Boehringer Ingelheim International GmbH, Catalent, Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Transfection & Selection Process segment, which is expected to reach US$31.1 Million by 2030 with a CAGR of a 7.9%. The Single Cell Cloning Process segment is also set to grow at 5.8% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $27.1 Million in 2023, and China, forecasted to grow at an impressive 5.5% CAGR to reach $23.0 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 179 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value (USD) in 2023 | $99 Million |
| Forecasted Market Value (USD) by 2030 | $150.7 Million |
| Compound Annual Growth Rate | 6.2% |
| Regions Covered | Global |
Key Topics Covered:
MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of COVID-19 and a Looming Global Recession
- Biotherapeutics Cell Line Development - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
MARKET TRENDS & DRIVERS
- Increasing Demand for Biologic Drugs Driving Cell Line Development Innovation
- Technological Advancements in Gene Editing Tools Like CRISPR-Cas9
- Rising Adoption of Automation and High-Throughput Screening in Cell Line Development
- Expanding Role of AI and Machine Learning in Cell Line Selection and Optimization
- Growing Need for Scalable and Stable Cell Lines in Monoclonal Antibody Production
- Increasing Focus on Personalized Medicine and Gene Therapies Boosting Cell Line Development
- Rising Investments in Biosimilar Development Creating New Opportunities
- Emerging Markets for Biotherapeutics Fueling Global Demand for Cell Line Development
FOCUS ON SELECT PLAYERS:Some of the 11 companies featured in this Global Biotherapeutics Cell Line Development market report include
- AGC Biologics
- Beckman Coulter, Inc.
- Becton, Dickinson & Company
- Boehringer Ingelheim International GmbH
- EMD Millipore Corporation
- Lonza Group Ltd.
- MilliporeSigma
- ProBioGen AG
- Selexis SA
- Sony Biotechnology Inc.
- Sysmex Corporation
- Thermo Fisher Scientific, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/cduwpa
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
